Abstract: Src homology 2 (SH2) domains are found in many intercellular signaltransduction proteins which bind phosphotyrosine containing polypeptide sequences with high affinity and specificity and are considered potential targets for drug discovery.
INTRODUCTION
Src homology 2 (SH2) domains are modules of about 100 amino acid residues that are found in many intracellular signal-transduction proteins, which bind phosphotyrosine containing polypeptide sequences with high affinity and specificity [1 -3] . The protein p56 lck is a Src-like, lymphocyte-specific tyrosine kinase, containing an SH2 domain that participates in signalling pathways initiated through the T-cell antigen receptor upon T-lymphocytes. The SH2 domain is thought to be responsible for the recruitment and regulation of p56 lck kinase activity [4 -7] .
Crystallography data has indicated that up to 30% of hydrogen bonding between high affinity phosphopeptides bound to the p56 lck SH2 domain can be attributed to the peptide backbone. The contacts made between the SH2 domain and the peptide backbone would be critical for specificity, and chemical alterations to the backbone of phosphopeptides could afford novel *Address correspondence to this author at the Division of Biochemistry and Molecular Biology, School of Biological Sciences, University of Southampton, Bassett Crescent East, Southampton SO16 7PX, U.K.; Tel: +44 (0) 23 80 594335; Fax: +44 (0) 23 80 594459; E-mail: rps2@soton.ac.uk high affinity motifs [8 -10] . Discovery of such peptide mimetics may result in new immunosuppressants and anticancer agents with inherent protease resistance.
Although several excellent reviews have appeared on SH2 domains in recent years [5, 7, 11 -16 ] the focus of this review is to summerise current understanding of p56 lck SH2 domain structure, mechanism and recent advances in drug discovery. The first part of the introduction briefly describes the immune system, T-cell maturation, major histocompatibility complex, structure of Tcell antigen receptor and associated proteins, T-cell responses to invasion to foreign antigens, immunoreceptor tyrosine-based acti-vation motifs, targets of antigen receptor signalling and protein kinases. The authors feel it important to discuss these facets before advancing to the main theme of the subject.
The vertebrate immune system has the ability to recognise and discriminate between a vast diversity of structures to detect the presence of infectious agents. This is accomplished with two related but distinct antigen recognition systems: Tand B-lymphocyte antigen receptors and immunoglobulins. Immunoglobulins are synthe-sised by B-lymphocytes in both secreted and membrane bound forms. Secreted antibodies bind to antigen and then interact with receptors on the surfaces of other immune system cells (such as macrophages, neutrophils, mast cells, and natural killer cells), the receptors then activate the various effector functions of these cells. The membrane bound forms serves as a component of the antigen receptor complex of B-cells.
There is a near-infinite diversity of antigen receptors as each T-, or B-lymphocyte precursor uniquely rearranges its antigen receptor genes, resulting in the expression of one or sometimes two antigen receptor molecules. In the absence of antigen, mature lymphocytes reside in a quiescent state. Antigen contact with those rare lymphocytes that can recognise that particular antigen induces these cells to become activated, to expand their numbers and, in the case of Blymphocytes, to produce antibodies, or in the case of T-lymphocytes, to perform other effector functions, such as cytotoxicity and secretion of immunoregulatory mediators called cytokines (also called lymphokines), such as interleukin-2 [17] .
T-lymphocytes are the primary effectors of cell-mediated immunity with subsets of T-cells maturing into cytotoxic (or killer) T-cells, and helper T-cells. Killer T-cells are capable of causing cell death by the lysis of viral infected or foreign cells, whilst helper T-cells activate B-lymphocytes to make antibodies via the production of lymphokines and direct cell contact [18] .
T-lymphocytes arise from bone marrow precursor cells that migrate to the thymus during fetal and early postnatal life, they differ from other immune effector cell types in that the pool of effector T-cells is established in the thymus early in life and is maintained throughout life by antigen driven expansion of long lived T-cells that reside primarily in peripheral lymph organs and recirculate in blood and lymph. Mature Tlymphocytes contribute 70 to 80 percent of normal peripheral blood lymphocytes (B-cells making up another 10 to 15%).
The earliest identifiable cells of T-cell lineage are prothymocytes located in the subcapsular cortical region of the thymus and are characterised by their expression of the sheep-erythrocyte-binding protein, CD11 (stage I of development). With further maturation, prothymocytes enter the inner thymic cortex, acquiring the cortical thymocyte protein CD6, and co-express T-lineage molecules CD4 and CD8 (stage II). More than 90% of stage II thymocytes that arise in the inner cortex die intrathymically, (self-reactive ones) with only a minority of thymocytes achieving phenotypic and functional maturity. This is as a consequence for the immature T-cells requirement for a stimulus through their antigen receptor for further development [19] . Mature T-lymphocytes are located in small foci within the inner cortex and throughout the thymic medulla and express the Tcell antigen receptor associated CD3 molecules (stage III). With maturity, T-lymphocyte subsets CD4 and CD8 are reciprocally expressed.
Antigenic differences between members of a species are called alloantigens, and when these play a determining role in the rejection of allogenic tissue grafts or foreign cells, they are called histocompatibility antigens. Evolution has conserved a single closely linked region of histocompatibility genes, the products of which are prominently displayed on the cell surfaces and provide a strong barrier to allotransplantation. The term Major Histocompatibility complex (MHC) refers to the gene products and genes of this chromosomal region. Structures bearing MHC antigens play a major role in immunity and in selfrecognition.
Three classes of gene products are encoded within the region of the MHC. Of these, class I and class II are important for self-nonself determination. Class I is expressed on the surfaces of nearly all cells, and consists of one heavy and one light polypeptide chain. Class II, expressed in activated T lymphocytes and B lymphocytes, consists of 2 polypeptide chains (α and β) of unequal length.
The T-cell antigen receptor, called TCR (or Ti), is a 90 kDa heterodimer composed of one 50 kDa and one 43 kDa B chain (α and β respectively). The α and β molecules possess amino acid sequence homology and structural similarities to immunoglobulin heavy and light chains. The TCR β chain contains 4 separately encoded regions, namely the V (variable), D (diversity), J (joining), and C (constant) regions. TCR α, however, only contains three; the V, J and C regions. During Tcell maturation the gene for the α and β chains undergo gene rearrangement culminating in the synthesis of the completed TCR molecule. The complete receptor complex is made up of many subunits as described below.
The most popular current theory for T-cell antigen receptor structure consists of seven subunits depicted in (Fig. 1) [5, 20] . The first subunit is the variable αβ hetero dimer, which are covalently linked and provide the binding site for antigen-MHC. Noncovalently associated with this are six invariant chains: CD3γ, CD3δ, two copies of CD3ε, and a CD3ζ homodimer.
In addition to the TCR, as discussed previously, the T-cells express other surface glycoproteins called "accessory" activation molecules which are known to play important roles during T-cell activation. These include the glycoproteins, CD4 and CD8, which are structurally related members of the immunoglobulin gene super family, but are highly divergent in their sequences. While CD4 is thought to be a monomer, CD8 can exist as αα homodimers or αβ heterodimers, the α and β chains being encoded by two distinct genes. The extracellular domains of CD4 and CD8 bind to regions of class II and class I MHC molecules respectively [21] .
Transfection experiments in CD4 -and CD8 -Tcells show that CD4 or CD8 expression significantly enhances the T-cell response when presented with sub optimal antigen stimulation when ever the TCR recognises the same MHC molecule as the CD4 or CD8 [22] . This suggests that they act as "co-receptors" of the TCR complex. Killer T-lymphocytes contain only CD8; whilst helper-inducer T-lymphocytes contain only CD4.
All cells, except red blood cells, can digest foreign material whether it be a virus, bacteria or another form. B-lymphocytes, and macrophages (monocytes if in the blood), obtain such foreign material either by anti-body mediated endocytosis or by non-specific endocytosis, respectively. Any of this digested material is then placed on the cell surface in association with MHC II. Binding of a helper T-cell TCR (in conjunction with CD4) to this antigen-MHC II complex results in the helper T-cell response. The program of early responses to antigen-receptor activation is similar to that evoked by many growth factors: rapid tyrosine phosphorylation, phosphatidyl inositol-specific phospholipase C (PLC) activation, elevation in cytoplasmic free calcium levels, and the activation of many serine and threonine kinases. This leads to the synthesis and secretion of lymphokines; which act mainly as T-and B-lymphocyte growth and maturation factors. Interleukin 2 (IL-2), for example, will initiate B-lymphocyte antibody synthesis and macrophage stimulation. Helper Tcells can therefore stimulate the immune response and also co-ordinate it.
Killer T-cells operate as the watchmen of intracellular invasion. Viruses and bacteria that gain access to the inside of a cell can be digested by their host. Some of these digestion fragments will then be associated with an MHC I. The complex is transported to and displayed on the plasma membrane exposed to the extra-cellular space to be scrutinised by killer T-cells. To ensure that killer T-cells do not destroy B-lymphocytes or macrophages, only non-immune cells have the ability to make MHC I. Killer T-cells only bind this form, and so can only act upon cells that have themselves been invaded. MHC II shows only foreign material that has been digested and destroyed intentionally, whilst MHC I shows only foreign material degraded from an organism that is propagating in a cell. Killer T-cells can recognise a foreign particle when it complexes to an MHC I. The TCR-CD8 complex binds to the MHC I system with very high affinity. Such recognition identifies the host as containing foreign material, hence infected. The resulting response by the killer T-cell is again mediated through a receptor tyrosine kinase cascade. The final result of the interaction is the maturation and division of the T-cell. Initially a limited amount of IL-2, and other interleukin synthesis and secretion predominates; these will stimulate the growth and maturation process. Also proteases and other proteins are produced to destroy the target cell. The most significant of these is perforin; this polypeptide will insert into the target cell plasma membrane and then polymerise into a non-specific ion channel. The target cell undergoes osmotic shock, and is there by lysed. By this means killer T-cells act to prevent bacterial or viral infection that starts with an intracellular offensive, the death of the infected cell is the price paid for the maintenance of the healthy organism.
Τhree CD3 chains (ε, γ, and δ) all have similar structures, with single extracellular immunoglobulin (Ig)-like domains and cytoplasmic domains of modest lengths. These cytoplasmic domains have functionally important regions of homology, first recognised by Reth [23] and subsequently named immunoreceptor tyrosinebased activation motifs (ITAMs) [24] . Each CD3 chain receptor has one ITAM of the consensus sequence D/EXXYXXL/IX 7 YXXL/I (where X denotes any amino acid). In contrast, the ζ chain has a very short extracellular domain and longer cytoplasmic domain which contains three ITAMs arrayed consecutively. ITAMs represent the basic signalling module of the antigen receptors which was first revealed in experiments in which chimeric transmembrane proteins containing ITAMs were expressed in lymphocytes [25] . Cross-linking of these chimeric proteins with anti-receptor antibodies induces signalling events that are very similar to those seen with intact receptors. (Crosslinking antigen receptors leads to tyrosine phosphorylation of ITAM-containing receptor subunits.) The importance of this has been demonstrated in mutants lacking the relevant ITAM tyrosine residues. Another characteristic of ITAMs is that they bind to intracellular tyrosine kinases, especially following phosphorylation [26] and are likely to play an important role in initiating the signalling reactions.
Prominent targets of antigen receptor signalling are similar to those seen in response to the tyrosine kinase growth factor receptors. Those that have recieved the greatest attention in lymphocytes have been phospholipase Cγ1 and γ2, phosphatidyl inositol 3-kinase and the Ras pathway [27] . The breakdown of phosphatidyl inositol (4,5)-bisphosphate and the subsequent elevation of intracellular levels of free calcium and activation of protein kinase C isoforms is thought to be important in a variety of inductions of gene expression in lymphocytes. In T-cells calcium elevation leads to activation of calcineurin, a serine/threonine protein phosphatase, which activates the cytoplasmic component of NFAT, a transcription factor important for activation of IL-2 gene expression in T-cells [28] . The Ras pathway is also important for IL-2 gene induction upon TCR stimulation [29] .
PROTEIN KINASES
The mechanism by which these targets are stimulated is not clear, as most signalling components do not bind efficiently to the antigen receptor complexes themselves. Recent attention has focused on interactions between Src family kinases and signalling targets.
The largest known protein superfamily is made up of protein kinases identified largely from eukaryotic sources. Indeed, it has been predicted that the mammalian genome contains over 2000 protein kinase genes which may account for an astonishing 1% of all genes [30, 31] . Protein kinases use the gamma phosphate of ATP to generate phosphate monoesters of protein alcohols (serine/ threonine) or phenolic (tyrosine) groups, and are related by virtue of their homologous catalytic domains which consist of 250 to 300 amino acid residues. Protein phosphorylation along with the cycles catalysed by G proteins and their associated factors, appear to represent the primary means for rapidly switching the activities of cellular proteins from one state to another. Protein cycles involve distinct reactions in the forward and reverse directions catalysed by protein kinases and phosphatases respectively. The equilibrium constants for kinases and phosphatases, together with the intracellular concentrations of ATP, ADP, and Pi ensure that in vivo a kinase will only phosphorylate and a phosphatase will only catalyse dephosphory-lation. Ther__ore the proportion of a phospho-to dephospho-protein can be varied from zero to one by modulating the catalytic efficiency of the protein kinase and/or phosphatase enzyme(s). The hydrolysis of ATP is a small price to pay to allow the control system to escape from the constraints of equilibrium.
Protein phosphorylation cycles are capable of signal amplification, and high sensitivity. Amplification refers to when the absolute concentration of the final target protein is much higher than that of the input signal. Sensitivity refers to the case where a small percentage change in the initial signal produces a much larger percentage change in the final response, this can occur when a kinase and phosphatase acting on a target protein are simultaneously modulated in opposite directions. Protein phosphorylation cycles also have the ability to act in protein kinase cascades (which should be thought of as branching networks rather than linear chains). These allow the summation of many different inputs into the cell to be processed into numerous outputs. They can also contain feedback loops which act both in the positive and negative directions. Many protein kinases are activated by phosphorylation, either by autophosphorylation or by phosphorylation of upstream protein kinases in a cascade [31] . It should be noted that protein phosphatases clearly play roles of equal importance in any protein phosphorylation cycle deactivating, or fine tuning a cascade response to a stimulus.
There are three subfamilies of protein kinases; serine/ threonine specific kinases (making up approximately 99% of all the kinases); tyrosine specific kinases (making up less than 0.1% of all the kinases) and kinases which show dual specificity to tyrosine and serine/ threonine. The tyrosine specific kinases are termed as "conventional protein-tyrosine kinases", and includes a number of enzymes with closely related kinase domains that specifically phosphorylate tyrosine residues; members including Src and yes. These enzymes were first recognised among retro viral oncoproteins [32 -35] and have only been found in metazoan cells where they are widely recognised for their roles in transducing growth and differation signals [36] .
THE ROLE OF P56 lck IN T-CELL ACTIVATION
Clues as to the identity of the kinases involved in phosphorylating ITAMs, and the cellular responses after TCR stimulation came from observations of the over expression of tyrosine kinases in lymphocytes with neoplastic malignancies such as leukaemia.
One protein tyrosine kinase discovered in this way by Marth et al., [4] was p56 lck , which was found by virtue of its augmented expression in two Moloney murine leukaemias. p56 lck is a typical non-receptor protein tyrosine kinase of the Srcfamily which is expressed almost exclusively in Tlymphocytes and natural killer cells [9, 13] .
A link between p56 lck and tumorigeneses was suggested by the finding that the LCK locus is a site of proviral insertion in some thymic lymphomas in mice [37 -39] . It was also found that the LCK gene in humans maps to chromosomal band 1q34 which is known to be a site of chromosomal aberrations in some T-cell tumours [40] . Later Abraham et al., [12] generated transgenic mice carrying the wild type LCK gene or a mutated LCK gene encoding a constitutively activated form of p56 lck (p56 lck F505). Mice expressing high levels of either p56 lck or p56 lck F505 developed thymic tumours. The sensitivity of thymocytes to p56 lck -induced transformation therefore suggested that p56 lck -mediated phosphorylation may stimulate lymphocyte proliferation. A recent study [41] has revealed that abberrant expression of p56 lck from the Lck type I promoter in colon carcinoma arises from transcriptional activation mediated by Ets-and HMG-related transcriptional factors.
In addition, T-cells that exhibit sub-optimal levels of p56 lck fail to show adequate TCRstimulated responses. This was illustrated by Strauss and Weiss [42] , who isolated mutants of the Jurkat T-cell line that failed to show increases in calcium levels, and tyrosine phosphorylation following TCR stimulation. Analysis of one of these mutants, JCaM1; revealed a fault in the expression of functional p56 lck . This lack of activity was caused in part by a splicing defect, and expression of the p56 lck cDNA in JCaM1 restored the cells ability to respond to TCR stimulation.
STRUCTURE OF P56 lck
p56 lck is comprised of a simple polypeptide chain of 509 amino acids with a predicted molecular weight of 58.097 kDa (56kDa on SDS-PAGE), the sequence is shown in (Fig. 2) [11] . The protein contains several distinct regions that are conserved in most protein tyrosine kinases, which are depicted in (Fig. 3) .
The protein tyrosine kinase domain, termed Src homology domain 1 (SH1) occupies the majority of the carboxyl half of the p56 lck protein. The ATP binding site is centred around Lys273, and an in vitro autophosphorylation site is present at Tyr394 which is not normally phosphorylated in vivo. The carboxy terminal tail of p56 lck has a negative regularity domain [13] , which in vivo represents the major site of phosphorylation at Tyr 505. Phosphorylation (thought to be mediated by the cellular kinase Csk) suppresses the catalytic activity of the enzyme. namely; the myristylation signal; the "unique" region; and the Src homology domain 3 (SH3). The myristylation signal (including the site of myristylation, at Gly 2) targets the kinase to the inner membrane thus allowing for assosiation to the TCR complex and other structures. The "unique" region is a sequence specific to each member of the Src family which binds to CD4 and CD8. The SH3 domain is thought to allow interactions with cytoskeletal constituents by binding to specific sequences containing proline residues [2, 43] , thus aiding its recruitment to a suitable substrate which exhibits these sequences. The SH3 structure has recently been solved [8b], which indicates that it is made up of a 60 amino acid residue section and exhibits a compact antiparallel β-sandwich structure composed of five β strands. The binding site for proline rich sequences is a hydrophobic "pouch" on the surface of this domain [45, 46] .
The middle portion of the protein contains the Src homology domain 2 (SH2) which mediates binding to cellular phosphotyrosine-containing proteins. A large proportion of the TCR-regulated substrates can associate with recombinant p56 lck SH2 domains in vitro [6] . Deletion of the SH2 domain greatly diminishes the ability of p56 lck molecules to enhance TCR-induced tyrosine protein phosphorylation. However, deletion also results in its constitutive activation, and leads to oncogenesis in rodent fibroblasts [12] . Thus the SH2 domain could be involved in both the recruitment of substrates and auto-regulation. To this end it has been postulated that the SH2 domain can bind intra molecularly with the phosphorylated Tyr505 to create an inactive "closed" conformation. Studies investigating the binding of phosphotyrosine peptides of the carboxyl terminus show that binding does occur, but with low affinity when compared to other phosphotyrosine containing peptides [47] . Thus the interaction between the SH2 domain and the carboxy terminus may be readily displaced when high-affinity tyrosine-phosphorylated sequences are presented.
Recently, a novel crystal structure showed a p56 lck fragment made up of the SH3 and SH2 domains interacting with each other, either within the presence of a phosphopeptide or without [8b]. This association could represent a possible method of inhibition by dimerisation, however, the myristylated version of p56 lck would be membrane bound, and the likelihood of two enzymes being able to rotate in such a way appears unrealistic.
THE KINASE DOMAIN (SH1)
Three roles can be ascribed to the kinase domain; (1) binding and orientation of the ATP phosphate donor as a complex with a divalent cation (usually Mg 2+ or Mn 2+ ); (2) binding and orientation of the protein substrate; (3) transfer of the γ phosphate from ATP to the acceptor hydroxyl residue of the protein substrate. The sequences of many protein tyrosine kinases catalytic domains share high sequence homology, which implies that they fold into topologically similar 3D core structures and impart phosphotransfer according to a common mechanism [31] . Twelve kinase domain residues are recognised as being invariant throughout the protein kinase superfamily. The pattern of amino acid residues found within some of the subdomains have been particularly well-conserved among the individual members of the different kinase families. The structure of the kinase domain in its activated form has been recently solved by Yamaguchi and Hendrickson [48] .
The kinase domain of p56 lck folds into a twolobed structure. The smaller N-terminal lobe is involved in anchoring and orienting the nucleotide. The larger C-terminal lobe is largely responsible for binding the peptide substrate and initiating phosphotransfer. The deep cleft between the two lobes is the site of catalysis, and contains the region known as the "catalytic loop" [49] . Activation of the kinase is thought to occur after auto-phosphorylation of Tyr394, which results in new hydrogen bonding interactions being created between the phospho group and the guanidine side chains of residues Arg387 and Arg363. This slightly shifts the kinases configuration, and culminates in a state of openness for the ATP binding cleft. It has been proposed by Yamagutchi and Hendrickson [48] that this conformation is impossible to obtain when the kinase domain is connected to the SH2 domain whilst the SH2 domain is occupied with its phosphorylated Cterminal sequence (phosphorylated at Tyr505), thus explaining the method of inhibition exhibited by the regulatory sequence.
p56 lck SH2 Domain SH2 domains can directly recognise pTyr, however, high affinity binding can only occur when the pTyr is embedded in a specific peptide sequence [2, 6] . Differences between the amino acid residues that make up SH2 domains account for their observed variation in specificity for different peptides. Even small pTyr-based peptides of no more than five residues have been shown to be capable of inhibiting a cascade by blocking an SH2 domain from interacting with its target pTyr on the receptor. The simplist mechanism of action is that interactions with pTyr-based peptides allow the recuitment of SH2-containing proteins to the plasma membrane which will increase their activity, either by direct phosphorylation,or by their close proximity to a membrane bound substrate, or by other less obvious means [2] . There has been recent developments in finding high affinity sequences that bind to the SH2 domains of p56 lck and other Src family tyrosine kinases ( Table 1 ). The primary and secondary structure of p56 lck SH2 domain is depicted in (Fig. 4) .
The highest affinity ligand to p56 lck known so far is an eleven amino acid residue phosphopeptide, EPQpYEEIPIYL derived from the hamster polyoma middle T-antigen (hmTpY324). The peptide has a dissociation constant of approximately 1nM to the p56 lck SH2, which is five-fold greater than that of the p56 lck carboxy-terminal tail sequence TEGQpYQPQP [50] .
Several crystal structures for the SH2 domain of p56 lck have been solved, some co-crystallised with phosphotyrosine containing peptides [8 -10, 50] . These studies have revealed that the SH2 domain is an independently folding hemispherical unit of about 100 amino acids, formed by two anti-parallel β sheets, and flanked by two α helixes [2 -3] . A high resolution X-ray structure of the SH2 domain complexed with the hmtpY324 sequence (Fig. 5) has provided molecular details revealing that most of the peptide is exposed to the solvent and the only significantly buried portions being the pTyr and Ile sidechains [8] . In most cases, pTyr peptides bind in an extended conformation, however flexibility allows more than one conformation. A complex has been identified where binding occurs via a β-turn geometry [52] .
The crystallography data for the hmTpY324/SH2 complex affords the following hypothesis about the interactions between the two molecules. Binding occurs via a short stretch of the peptide (pY+4 to pY-2), the majority of the binding energy originating from a network of hydrogen bonds formed when the essential phosphotyrosine residue locates into a deep hydrophilic pocket. A smaller contribution to the binding energy comes from the isoleucine residue at the pY+3 position, which is accommodated in a deep hydrophobic pocket. The residues at pY+1 and pY+2 do not appear to insert into any pocket in the SH2 domain. The side chain of the pY+1 residue, a glutamic acid, lies across the face of the SH2 domain and could form several interactions with it, whereas the side chain of pY+2, also a glutamic acid residue, projects away from the surface into solution. The residues N-terminal to the proline at pY-2, and also the residues Cterminal to the proline at pY+4, turn away from the surface of the SH2 domain and are therefore not expected to contribute to any binding interactions. Interestingly, up to 30% of the hydrogen bonding interactions are initiated through the peptide backbone. Fig. (4) . The primary and secondary structure of p56 lck SH2 domain, α-helixes are labelled alphabetically whereas β-sheets are labelled numerically (reference 8).
It was hypothesised that due to the small number of binding points in a restricted area around the phosphotyrosine between the hmTpY324 and the SH2 domain, a shorter peptide might be employed in the place of hmTp324 with comparable affinity to it. In fact, investigations using phosphotyrosine containing peptides based upon the residues of pY-1 to pY+4 have been made [8a], which still show significant levels of binding (0.17µM, ID 50 ).
MODE OF ACTION OF P56 lck IN SIGNAL PATHWAYS
The mode of action of p56 lck in TCR stimulated signal pathways was first postulated by Rudd et al., [64] , who made the observation that the T lymphocyte surface glycoproteins CD4 and CD8 were physically associated with p56 lck , and can be made to co-immunoprecipitate with them in human and mouse T-cells. Additionally it was found that antibody-mediated cross-linking of CD4 molecules stimulated p56 lck activity [65] . It was therefore proposed that when CD4 or CD8 recognise the same binding motif on an antigen as the TCR, the p56 lck is brought into close proximity to its substrate (somewhere on the cytoplasmic side of the TCR), and in so doing is able to induce signal transduction.
The interaction between p56 lck and CD4/CD8 occurs via a specialised cysteine containing motif in p56 lck 's unique N-terminal domain that compliments a related motif in the cytoplasmic regions of the co-receptors. The exact area was pin-pointed by Turner et al., [66] who employed co-precipitation experiments between various CD4/CD8 mutants (Cys to Ala), and p56 lck mutants (also Cys to Ala), to elucidate that p56 lck Cys 20 and p56 lck Cys 23 were critical for association with the CD4/CD8. 
THE CRITICAL INVOLVEMENT OF P56 lck IN THE REGULATION OF THYMOCYTE DEVELOPMENT
The relationship of the interaction between p56 lck and thymocyte development was proposed by Molina [67] who generated a p56 lck null mutation in embryonic stem cells. The resultant p56 lck deficient mice were healthy and fertile under pathogen free conditions, but histology showed a thymic cortex sparsely populated with lymphoid cells and pronounced thymic atrophy, with a dramatic reduction in the double positive (CD4 + CD8 + ) thymocyte population. Mature, single positive thymocytes were not detectable at all, and there were only a few circulatory peripheral T-cells. In a more recent study Seavitt et al. [68] has reported that thymocyte developement requires the dephosphorylation of the inhibitory site in Lck by CD45.
These observations can be explained by considering the role the cell surface accessory glyco-proteins have in the early stages of thymocyte production. CD4 and CD8 mediated signals in conjunction with the TCR, are important during the positive selection of T-cells in the thymus [69 -70] . The signalling pathways involved in the expansion phase or the selection event of the double positive thymocytes observed in p56 lck deficient mice is impeded, and therefore implicates p56 lck in these signalling pathways [71] .
REGULATION OF P56 lck ACTIVITY
Resting cells maintain a substantial pool of dephosphorylated p56 lck , due to the action of the transmembrane protein tyrosine phosphatase CD45. Indeed, mutant T-cell lines have been found that are CD45 negative, and which show defective TCR responses to antigen stimulation in parallel with a two-to-three-fold increase in phosphorylation at Tyr505 on p56 lck [72] . Therefore it is possible that p56 lck is activated through dephosphorylation of Tyr505, by CD45. Recently, Franklin and co workers have reported calcium-induced p56 lck phosphorylation in human T lymphocytes [73] .
It must also follow that the kinase responsible for deactivation of p56 lck has a very important role to play in the TCR-antigen stimulated signal pathway. C-terminal Src kinase (Csk) protein tyrosine kinase has been shown to be able to phosphorylate the p56 lck negative regulatory site, Tyr505 and other Src family member's regulatory sequences in a variety of cell types [74] . Csk is expressed ubiquitously but is highly concentrated in the thymus, spleen and the developing brain. It has been found that TCR stimulation is rapidly followed by an increase in Csk activity in T-cells [75] which may be for a negative feedback loop for TCR signalling, however, Csk can also phosphorylate CD45, increasing its activity and therefore promoting TCR signalling, indicating that the regulatory interactions here may be very complex [76] . (Table 2) shows the positions that Csk phosphorylates of Src family negative regulatory sites. Csk's wide specificity does not make it an attractive target for artificial control, however, its importance is illustrated by the discovery that over expression of Csk in T-cells inhibits the response of the TCR stimulation [77] .
OTHER KINASES INVOLVED IN TCR STIMULATED SIGNALLING FynT
The signalling cascade initiated by TCR stimulation, becomes more complex with another player, p59 fynT . The Src family protein tyrosine kinase p59 fynT was originally identified in fibroblasts in endothelial cells and subsequently in lymphocytes [78 -79] . Two isoforms have been defined (both 59 kDa on SDS-PAGE, which are generated by splicing of alternate seventh exons and differ over a 50 residue segment at the junction of the SH2 and kinase domains), with p59 fynT mostly confined to lymphoid lineage, and p59 fynB which is more widespread but especially highly expressed in neural tissue [80] . It has been demonstrated that p59 fynT is involved in T-cell signalling [11] . p59 fynT is expressed in both B and T lymphocytes but is present at highest levels in mature CD4 + or CD8 + thymocytes, and in peripheral T-cells.
Like other Src-family protein tyrosine kinases, p59 fynT has a negative regulatory region via phosphorylation of Tyr528 [81] , SH1, SH2, SH3 regions, and a region that may be myristylated at the N-terminal. It could therefore be tightly associated with the inner membrane, however, there is a ten amino acid sequence located at the Nterminus which mediates a low stoichiometry association with the ζ chain of the T-cell receptor, and it may be bound there. p59 fynT is not exclusive to lymphocytes, and its absence from T-cells although causing some inhibition of T-cell receptor signalling, does not stop it [82 -83] , implying that its cellular function can be negotiated by other means available to the cell.
ζ-Chain Associated Protein
In addition to the kinases p56 lck and p59 fynT , there is another TCR-associated polypeptide, called the ζ-chain associated protein (ZAP70), a 70 kDa protein tyrosine kinase expressed only in Tand natural killer cells, and which is present at all stages of thymocyte development. The protein has two SH2 domains, no SH3 domain, and is not myristylated. Therefore it may only be recruited by its SH2 domains to the TCR complex [84] .
Recently, patients with T-cell immunodeficiency have been described who had ZAP70 gene modulations that abolished functional ZAP70. T-cell development was perturbed in these patients but not completely blocked. The resulting T-cells were unable to signal through their TCR, demonstrating the critical importance of ZAP70 [85 -87] .
ROLE OF P56 lck IN ZAP70 RECRUITMENT AND ACTIVATION
ZAP70 has been shown to be tyrosine phosphorylated after TCR stimulation [18] and some recent observations indicate that to achieve a strong in vivo phosphorylation (and also to phosphorylate other cellular proteins in T-cells), ZAP70 must be co-expressed with p56 lck or p59 fynT [84, 88] . Further, it has been found that p56 lck interacts physically with ZAP70 [89] and therefore ZAP70 may be a substrate for it.
It is thought that p56 lck phosphorylates the TCR ζ and ε subunits at ITAM sequences, which allows for the association of ZAP70 with them, it could follow that p56 lck then activates ZAP70 by phosphorylation, or by binding via its SH2 domains, the ZAP70 is forced into an active conformation, thus conferring the TCR stimulated signalling response [53] .
MODEL FOR ACTIVATION OF THE TCR
When all the detective work is put together, a tentative hypothesis can be put forward as to the events that occur in the cytoplasm after TCR stimulation by the MHC presenting antigen in Tcells (Fig. 6) . Cross linking of TCR with the CD4/CD8-p56 lck by multivalent antigen leads to phosphorylation of the target tyrosines on the TCR complex at the ε and ζ subdomains by p56 lck (and/ or p59 fynT ), this provides binding sites for the cytoplasmic tyrosine kinase ZAP70 which uses its two SH2 domains to bind doubly tyrosine phosphorylated sequences on ζ or ε. p56 lck may also bind to phosphorylated sequences on the TCR complex and phosphorylate other ITAM sequences throughout the CD3, which may serve as a positive feedback loop for efficient phosphorylation and activation of the TCR complex. Next the p56 lck phosphorylates the bound ZAP70 thereby activating ZAP70 which inturn phosphorylates signalling targets. It must be noted that p56 lck and p59 fynT are also activated by TCR cross-linking, and so may participate in the phosphorylation of key signalling targets.
P56 lck SH2 DOMAIN DRUG DISCOVERY
The artificial regulation of the kinase activity of p56 lck 's is an attractive target for the pharmaceutical industry due to its exclusive expression in lymphocytes, its requirement for a proper immune responses and the development of T-cells. As discussed, p56 lck may be recruited via its SH2 domain and regulated by the phosphorylation or dephosphorylation at Tyr505 through the actions of the kinase Csk and phosphatase CD45 respectively. It is therefore, not surprising that functional perturbation in these cell regulatory processes may lead to many diseases such as cancer, osteoporosis, allergy, asthma, inflammatory and other diseases ( Table 3) . Although SH2 domains have been reviewed recently [15, 16] , the main focus of this review is to summerise more recent advances on drug design with an emphasis on p56 lck SH2 domain and evaluate potential future targets. Many laboratories are currently researching the synthesis of molecules which can bind tightly to the SH2 domain of p56 lck , hindering substrate recruitment, and thereby artificially controlling its influence upon T-cells to generate immunosuppressants and anti-cancer agents.
Recent advances in recombinant DNA technology have made available virtually unrestricted quantities of proteins representing important pharmacological targets and have provided new directions to drug discovery. In these approaches, structural biochemical methods Fig. (6) . Model for the activation of tyrosine kinases by the TCR (Adapted from refernce 18). Cross-linking of the TCR and CD4/ CD8 to a multivalent antigen presented on the MHC via an antigen presenting cell (a), leads to the recuitment of p56 lck (via interactions with the membrane and CD4/ CD8 cytoplasmic tail), and then the phosphorylation of ITAM tyrosines on both the ζ and ε chains of CD3 (depicted by small grey circles). This provides binding sites for the cytoplasmic tyrosine kinase ZAP70 (depicted as the grey oval), which probably uses its two SH2 domains to bind to the two phosphorylated ITAM sequences on the ζ chain (b). ZAP70 is subsequently phosphorylated and therefore activated by p56 lck and can then phosphorylate down stream targets involved in the TCR response. p56 lck , or p56 fyn may then bind to the ε chain via its SH2 domain and participate in the phosphorylation of key signaling targets (c).
such as protein crystallography or nmr, in combination with the methods of computational chemistry are used to elucidate the precise interactions between inhibitors and their target enzymes. Such information may be useful to improve design and synthesis of more potent and selective inhibitors. The large number of crystal structures of SH2 domains complexed with inhibitors solved in numerous laboratories [8] [9] [10] 50] have indicated that the concept of structurebased drug design is widely pursued in the search for new classes of therapeutics for the treatment of the aforementioned diseases ( Table 3) . It has been well documented that the p56 lck SH2 domain displays high specificity for the sequence pYEEI [47, 51] . Structural information available from high resolution crystal structures of Src and Lck SH2 domains complexed with high affinity pTyr containing peptide ligands have revealed strong interactions between the protein and pTyr and Ile residues through hydrogen bond network [8] [9] [10] . These studies have also shown that the SH2 binding sites for Lck and Src are almost identical and the tetrapeptide pYEEI 9 forms the basis of an attractive structure-based design of effective inhibitors for both Src and Lck SH2 domains. Furthermore, structure activity relationship studies have indicated that a wide range of amino acid substitutions can be tolerated at both pY +1 and pY +2 positions (Fig. 7) as exemplified by the compounds Ac-pYLEI 10 (K D = 0.1 µM) and AcpYELI 11 (K D = 0.1 µM) displaying binding affinities and potency comparable to that of compound 12 (R = Ac, K D = 0.1 µM) [97] .
Although peptide ligands bind to SH2 domains, some of these molecules suffer from scarce solubility in aqueous solvents, poor cell permeability due to high ionic charge at physiological pH, rapid in vivo degradation and hence are not suitable as drug candidates. To some extent these problems have been addressed in recently reported nonhydrolysable phosphate mimics [57-58, 63, 98] , reduced size and charge peptidomimetics [15, 63, 99] and novel prodrug approaches [90, [100] [101] .
The hydrolytic lability of the tyrosine phosphate to cellular protein tyrosine phosphatases has led to the design and It was envisaged that additional sites for chemical alteration of tyrosine would be at the phenolic ring. The compounds 24 -26 were introduced into the peptide hmTpY324 sequence to see if the alteration in hydrophilicity of the phenolic ring might allow for its insertion into the phosphate binding pocket, thus conferring binding to the SH2 domain of p56 lck . However, the bead binding screening assay of peptides 1, 27 -32 (Table 4) indicated that fluorine substitutions into the phenolic ring are not tolerated even when the phospho group was present [61] .
Peptide binding studies with the p56 lck SH2 domain have shown that the presence of a functional group or an amino acid residue Nterminal to the phosphotyrosine to be important for binding affinity [52] . Simply acetylating the α-amino group of the phosphotyrosine increases binding. Hence, a peptide of only two to three residues with suitable alterations can create effective binding.
In the last few years there has been enormous progress in the development of potent , stable and Fig. (7) . Chemical structures of high affinity SH2 domain binding peptides. (Fig. 9) and (Table 5 ) respectively.
A new class of structure-based anti-SH2 peptidomimetic, 46 ( Fig. 10) incorporating an urea function as a peptide backbone alteration has met with some success [15, 56] . The crystal structure of compound 46 complexed with Src-SH2 domain has revealed a unique mode of binding of the ligand with the protein. The observed structural water displacement in the complex has been attributed to the ureido function.
In recent years, synthetic combinatorial libraries have become the most important tool for the design and discovery of potential drug candidates for the pharmaceutical industry [107 -108] . This powerful technique is based upon the synthesis and screening of vast numbers of different compounds in an efficient, fast and inexpensive manner. The library technique can be integrated to rational drug design through structure activity studies and to traditional medicinal chemistry. The approach can facilitate the rapid optimisation of lead compounds for further design and exploitation.
We have recently reported the application of tri-tert-butoxysilyl (T-tBos) of amino acids in peptide synthesis upon the solid phase from N to C direction [109] . The N to C methodology has been successfully employed in a variety of peptide backbone modifications in our laboratories [110] . This above strategy was adapted in the generation of a hexaphosphopeptide combinatorial library, Xurea-pY-X-X-X-X, where X represents all amino acids except Cys, Met and Trp to investigate the sequence specificity of the peptide binding site of p56 lck SH2 domain. The potent ligands, A-ureapYEEIP, 52 and D-urea-pYRTFG, 53 ( Fig. 10) were selected from a pool of candidates, 47 -53 as shown in (Table 7) . In a competitive ELISA study the compounds 52 and 53 competed almost as well as the hmTpY324 sequence (IC 50 = 34 nM). The SAR of the corresponding non-urea compounds 54 and 55 revealed the significance of the urea bond in compounds 52 and 53 as illustrated in (Table 6 ). It was postulated that the increase in binding affinity could be attributed to the additional hydrogen bond interactions between the urea bond and the SH2 domain [111].
Our results are further substantiated by a recent study by Plummer et al., [56] which describes the synthesis of small, nonpeptide, Src SH2 domain phosphotyrosine analogues, phospho-p-hydroxybenzyl-succinic acid (which has an additional CH 2 between the α-carbon and the carboxyl) used at the pY site. In modelling studies, the carboxyl of the phosphotyrosine analogue formed a bifurcated hydrogen bond to an arginine in the SH2 domain which would not be physically possible for peptide bond or an amino terminus of a non modified ligand to make. The Src and the p56 lck SH2 domains are very similar, and it is likely to be possible that the urea bond inserted in our study (compounds 52 and 53) could form hydrogen bonding interactions in a very similar manner, as spatially a urea bond could be superimposed upon the phospho-p-hydroxybenzyl-succinic acid analogue. Indeed, Plummer et al., further describe the insertion of urea bond to gain such affects as shown by compound 46 in (Fig. 11) . It is hoped that the lead compounds obtained in the above study would have potential for development into therapeutic agents.
CONCLUSIONS
In this review the authors have addressed the current understanding on the structure, mechanism and the significant achievements on the development of novel inhibitors of SH2 domains Fig. (11) . Diagram exhibiting the alignment of the carboxyl of the phosphotyrosine analogue phospho-p-hydroxybenzylsuccinic acid, and the ureido function of compounds 46, 52 and 53. Phospho-p-hydroxybenzyl-succinic acid was found to form hydrogen bond interactions with the Src SH2 domain when inserted at the "N"-terminal of a suitable peptide [56] , the urea bond, as indicated could be superimposed with the analogue, and it is postulated that it could form similar hydrogen bonding interactions with other SH2 domains. over the last few years. A number of X-ray structures of SH2 domains complexed with a variety of inhibitors have been solved and have provided a wealth of information about the mode of interactions between the inhibitor-protein complex. However, more structural information and inhibitory studies are required to unravel the complex mechanisms which are otherwise not well understood. This will undoubtedly enable us to design more potent, selective and stable inhibitors for SH2 domians.
